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Clinical research into consciousness has long focused on cortical
macroscopic networks and their disruption in pathological or
pharmacological consciousness perturbation. Despite demonstrat-
ing diagnostic utility in disorders of consciousness (DoC) and
monitoring anesthetic depth, these cortico-centric approaches
have been unable to characterize which neurochemical systems
may underpin consciousness alterations. Instead, preclinical exper-
iments have long implicated the dopaminergic ventral tegmental
area (VTA) in the brainstem. Despite dopaminergic agonist efficacy
in DoC patients equally pointing to dopamine, the VTA has not
been studied in human perturbed consciousness. To bridge this
translational gap between preclinical subcortical and clinical
cortico-centric perspectives, we assessed functional connectivity
changes of a histologically characterized VTA using functional
MRI recordings of pharmacologically (propofol sedation) and path-
ologically perturbed consciousness (DoC patients). Both cohorts
demonstrated VTA disconnection from the precuneus and poste-
rior cingulate (PCu/PCC), a main default mode network node
widely implicated in consciousness. Strikingly, the stronger VTA–
PCu/PCC connectivity was, the more the PCu/PCC functional con-
nectome resembled its awake configuration, suggesting a possible
neuromodulatory relationship. VTA-PCu/PCC connectivity in-
creased toward healthy control levels only in DoC patients who
behaviorally improved at follow-up assessment. To test whether
VTA–PCu/PCC connectivity can be affected by a dopaminergic ag-
onist, we demonstrated in a separate set of traumatic brain injury
patients without DoC that methylphenidate significantly increased
this connectivity. Together, our results characterize an in vivo do-
paminergic connectivity deficit common to reversible and chronic
consciousness perturbation. This noninvasive assessment of the
dopaminergic system bridges preclinical and clinical work, associ-
ating dopaminergic VTA function with macroscopic network alter-
ations, thereby elucidating a critical aspect of brainstem–cortical
interplay for consciousness.
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Delineating the neural underpinnings of consciousness is ofbasic scientific and clinical importance, both to understand
its reversible suppression during sedation/anesthesia (1) and to
allow informed treatment choices for patients with chronic dis-
orders of consciousness (DoC) (2). Striking parallels between
these perturbed states of consciousness have been characterized
using human neuroimaging, which converge in particular on the
default mode network (DMN). This prominent large-scale net-
work progressively loses functional connectivity integrity with
increasing severity in DoC (3, 4) and also with increasing depth
of anesthesia (5, 6). In both pharmacologically and pathologi-
cally perturbed consciousness, key DMN nodes in the posterior
cingulate cortex (PCC) and precuneus (7, 8) show disrupted
brain-wide functional connectivity associated with loss of con-
sciousness (9). These macroscopic phenomena have demon-
strated some diagnostic and prognostic value for DoC patients
and form empirical bases for contemporary theories of con-
sciousness (4, 10–13). However, these cortico-centric perspec-
tives have remained inherently unable to address whether
specific neurochemical systems may mediate perturbed con-
sciousness and the associated macroscopic network changes. The
delineation of these neurochemical drivers of consciousness is
key to the identification of amenable therapeutic targets in DoC
and for the understanding of anesthetic mechanisms—and as
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such for the formulation of an integrated clinical account of
consciousness.
To this end, preclinical work has focused in on the brainstem
neurotransmitter nuclei based on findings across a wide range of
experimental animal work utilizing anesthetic drugs and lesion
approaches. The transmitter systems studied in this context
range from glutamate and glycine, over orexin and histamine, to
acetylcholine and the biogenic amines (14). Among them, in
particular the dopaminergic system, has emerged as a candidate
neurochemical driver of consciousness due to its consistent im-
plication in preclinical animal studies and clinical DoC contexts.
Preclinically, Palmiter and colleagues demonstrated that
dopamine-deficient mice were behaviorally unconscious but that
retroviral restoration of dopaminergic signaling reversed asso-
ciated behavioral deficits (15). The source of the relevant do-
paminergic signaling was subsequently identified to be the
ventral tegmental area (VTA), the main dopaminergic brainstem
nucleus. Both optogenetic (16) and pharmacological VTA acti-
vation (17) acutely promote wakefulness in rodents. Critically,
electrical and optogenetic (18) stimulation of the VTA (but not
substantia nigra) can even reverse the sedative effects of pro-
pofol (19)—whereas lesions to the VTA lengthen recovery times
following propofol anesthesia in rodents (20). More broadly,
methylphenidate-induced reversal of propofol anesthesia in rats
is also suggested to act primarily via a dopamine-dependent
mechanism (21, 22). These preclinical findings implicate do-
paminergic signaling from the VTA as a tonic regulator of
wakefulness.
While equivalent experiments cannot be carried out in humans
due to their invasiveness, the relevance of dopamine has equally
been revealed in clinical settings through reports of beneficial
effects of various dopaminergic agonists in DoC patients. These
drugs include levodopa (23), bromocriptine (24), methylpheni-
date (25), and amantadine (26, 27), with further promising re-
sults from past and ongoing small-scale trials of apomorphine
(28). The corresponding and long-standing idea of dopami-
nergic dysfunction in DoC (29) is corroborated by a recent
11C-raclopride positron emission tomography (PET) study which
indicated impaired presynaptic dopamine release in minimally
conscious state (MCS) patients (30). However, despite this
Fig. 1. VTA disconnects stepwise and reversibly from PCu/PCC in propofol sedation. (A) In awake participants, the VTA ROI showed resting-state functional
connectivity to PCu/PCC as well as hippocampal, insular, and cerebellar areas (Table 1). Under mild (B) and moderate (C) propofol, the VTA showed a stepwise
loss of connectivity specifically with precuneus and posterior cingulate. (D) In recovery, connectivity to precuneus and PCC was regained (blue). (E) Anatomical
slice display, centered on peak MNI coordinates, of cluster from C, which was used for extraction of subject-specific VTA-to-PCu/PCC connectivity values. (F)
The higher the effective propofol dosage was in participants’ plasma, the more disconnected the VTA was from the PCu/PCC cluster (i.e., lower connectivity)
across all experimental conditions. (G) The strength of this connectivity was positively predictive of how reliably participants were able to discriminate novel
and familiar stimuli from a semantic processing task performed at each sedation level, measured as the sensitivity index d′. The colored dots in graphs are
individual participants. The black line is the overall regression line without participant variable. Statistical thresholds for connectivity changes were voxel level
P < 0.005 (uncorrected) and cluster level P < 0.05 (FWE corrected). Brains are in neurological orientation, that is, “L” is left. Renderings were made using the
CONN toolbox three-dimensional template.
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dopaminergic focus which parallels the preclinical implications
of dopamine, research in humans has left unanswered whether
pathological and pharmacological consciousness perturbations
may arise due to impaired function of the main dopaminergic
nucleus, the VTA. Consequently, the characterization of VTA
function in humans with consciousness perturbations holds crit-
ical translational potential and could strongly enhance ongoing
dopaminergic drug trials.
Explicitly, dysfunction of the VTA could also underpin mac-
roscopic network alterations consistently observed in states of
lowered consciousness, since dopamine acts as a neuromodulator
(31–33). Neuromodulation is the process by which diffusely re-
leased nonclassical transmitters, such as dopamine, can alter
intrinsic electrochemical and synaptic properties of neurons (32)
and thereby change input–output relationships at all scales of
brain organization (33, 34). This allows the finite number of
anatomical connections in the brain to integrate into diverse
meso- and macroscopic functional configurations (32, 33). As
dopamine is diffusely released from the VTA to almost all cor-
tical structures (31), dopaminergic neuromodulation is a strong
candidate to mediate macroscopic network-level effects. This has
been demonstrated for catecholaminergic manipulation more
broadly in healthy individuals using functional MRI (fMRI) (35,
36) and is corroborated specifically for dopamine by the obser-
vation that posteromedial D2/D3 receptor occupancy measured
with [18F]-fallypride PET is associated with whole-brain DMN
integrity in healthy individuals (37). Critically, these dopami-
nergic effects have neither been tested in pharmacological and
pathological consciousness perturbation despite the many im-
plications of dopamine nor have they been associated with the
dopaminergic source nucleus, the VTA. Conversely, rather than
representing the loss of a crude “activating signal” (38), VTA
dysfunction could reflect altered neuromodulatory environ-
ments, which may precipitate neural phenomena such as DMN
disintegration in perturbed consciousness. As such, delineating
relevant VTA function holds the potential to translationally scale
insights from experimental models of VTA function to human
in vivo neuroimaging contexts of altered networks.
We consequently aimed to explore how this dopaminergic
nucleus behaves in perturbed consciousness in resting-state
fMRI (rs-fMRI) data from healthy volunteers undergoing pro-
pofol sedation (n = 24) and patients with chronic DoC (n = 22)
using an anatomically and histologically validated VTA region of
interest (39). We chose rs-fMRI because of its better spatial
resolution in comparison to PET and as the latest guidelines by
UK and US clinical bodies recommend the use of this nonin-
vasive imaging technique in DoC patient management (40).
Explicitly, we hypothesized that 1) alterations in VTA functional
connectivity would occur across both reversible and pathological
perturbation of consciousness, that 2) these alterations should
relate to whole-brain connectivity changes, behavior, and/or
outcome, and that 3) VTA functional connectivity may be af-
fected by a dopaminergic agonist.
Results
The VTA Loses Precuneus and Posterior Cingulate Connectivity during
Propofol Sedation and in DoC. As the VTA’s involvement in sed-
ative mechanisms has been established in preclinical models
(41), we began by assessing the VTA’s functional connectomic
changes during propofol sedation using the histologically char-
acterized VTA region of interest (ROI) from the Harvard as-
cending arousal network atlas [HAAN (39)]. In awake
volunteers, the VTA showed functional connectivity to the pre-
cuneus, PCC, brainstem, cerebellum, insula, and hippocampus
(Fig. 1A and Table 1), consistent with previous reports by Bär
and colleagues (42). However, upon propofol administration,
whole-brain contrasts between awake versus mild (Fig. 1B) and
awake versus moderate sedation (Fig. 1C) showed that the VTA
lost connectivity exclusively with a cluster in the precuneus and
PCC. The connectivity of the VTA to these areas re-emerged
during recovery from sedation (Fig. 1D). The connectivity
strength of the VTA to the precuneus and PCC cluster was
negatively correlated with participants’ plasma propofol con-
centrations across all experimental conditions (r = −0.53, P <
0.001; Fig. 1 E and F).
The healthy control group used for comparisons with the DoC
patients showed equivalent awake connectivity of the VTA but
displayed a small additional connectivity cluster in the thalamus
(Fig. 2A). When DoC patients were compared to controls, the
VTA showed reductions in functional connectivity with the
precuneus and PCC, resembling the changes seen in propofol
sedation (Figs. 1 A and B and 2B). In addition, we also found
reductions in connectivity of the VTA to the mediofrontal cortex
(another hub of the DMN). The VTA in DoC patients also
showed some increases in functional connectivity to other brain
areas, largely to subcortical regions and the hippocampus
(Fig. 2B and Table 1). The clusters of VTA disconnection that
we observed in both propofol sedation and DoC cohorts over-
lapped spatially in the precuneus and posterior cingulate (clus-
ters hereafter: PCu/PCC) across both conditions.
VTA–PCu/PCC Connectivity Is Associated with Relevant Behavior in
Propofol Sedation and in DoC Patients. To answer whether the
VTA’s connectivity loss to PCu/PCC was associated with be-
havior, we extracted β-coefficients from the general linear model
for VTA–PCu/PCC connectivity and correlated these with rele-
vant behavioral measures for each cohort.
For the propofol cohort, we tested whether stimuli presented
for a semantic decision task during the awake and sedated states
were subsequently identified as familiar or novel after recovery
from sedation (see Materials and Methods). The participants’
ability to correctly classify stimuli as novel or familiar was
quantified as the sensitivity index d′ (d prime), a proxy for ex-
plicit memory formation with conscious cognitive access (43).
We found that the d′ score covaried positively with VTA–PCu/
PCC connectivity during propofol-based perturbation of con-
sciousness (r = 0.4, P < 0.001, Fig. 1G).
Similar behavioral measurements in patients with DoC are
impossible. We nevertheless aimed to assess whether VTA–PCu/
PCC connectivity may be related to behavior or outcome.
There was no significant correlation with the coma recovery
scale—revised (CRS-R; r = 0.2, P = 0.373) or its arousal subscore
(r = 0.41, P = 0.066) at time of scan. However, we more closely
examined the patients within our sample who had follow-up
scans (n = 7, mean elapsed time 509 ± 131 d). Among this
subsample, two patients improved in terms of CRS-R and remain
alive, whereas the remaining five further deteriorated and sub-
sequently deceased. Although the small subsample size makes
meaningful statistics impossible, it is relevant to report that the
two alive and improved patients showed a re-emergence of
positive VTA–PCu/PCC connectivity at their second imaging
assessment, improving from negative VTA–PCu/PCC connec-
tivity recorded at the previous assessment. In contrast, the pa-
tients who deteriorated (lower CRS-R scores) and deceased
after the imaging follow-up had maintained and/or worsened
negative VTA–PCu/PCC connectivity (SI Appendix, Table S1).
VTA–PCuu/PCC Connectivity Strength Is Associated with PCu/PCC
Whole-Brain Connectome Disintegration. The areas of disconnec-
tion we observed for the VTA were in the PCu/PCC and dis-
played resting connectivity to key nodes of the DMN in whole-
brain analyses in both control cohorts (SI Appendix, Fig. S1 and
Table S2). As both DMN intrinsic connectivity and its functional
relationships with other brain regions are commonly altered
during perturbations of consciousness, we next asked whether
changes in this large-scale network could be driven by altered
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VTA–PCu/PCC connectivity—possibly reflecting altered neuro-
modulation of the PCu/PCC, precluding correct functional cir-
cuit assembly (32). Because neuromodulation itself cannot be
measured with any single-modality neuroimaging technique, we
sought to approximate a VTA neuromodulatory relationship
by different means. We examined whether VTA–PCu/PCC
connectivity strength in perturbed consciousness covaried with
brain-wide connectivity alterations between the PCu/PCC and
other brain regions (within and outside the DMN) in perturbed
consciousness (see Materials and Methods and SI Appendix, Fig.
S2 for full “downstream” brain-wide connectivity changes).
In the case of propofol sedation, the PCu/PCC cluster from
which the VTA disconnected showed no reductions in connec-
tivity with any part of the brain that reached significance.
However, it showed significant increases in connectivity to areas
that are not part of the canonical DMN (Fig. 3 and SI Appendix,
Fig. S2B and Table S3). In repeated measures correlations across
all sedation conditions, PCu/PCC connectivity to these pre-
dominantly visual non-DMN areas was negatively correlated
with VTA–PCu/PCC connectivity strength (r = −0.37, P = 0.001)
(Fig. 3).
The PCu/PCC cluster in patients with DoC showed wide-ranging
reductions in connectivity, predominantly with areas classically
identified as DMN regions (Fig. 4A, red and SI Appendix, Fig. S2A
and Table S3). Concomitantly, the PCu/PCC also showed gains in
connectivity to occipital regions in the DoC patients (similar to
changes seen with propofol sedation in healthy volunteers), with
additional connectivity gains to sensorimotor, precentral, post-
central, and anterior cingulate cortices (Fig. 4B, blue). The strength
of PCu/PCC connectivity to clusters with which it lost connectivity
covaried directly with changes in VTA–PCu/PCC connectivity (r =
0.5, P = 0.017; red, Fig. 4A), indicating a potential modulatory role
of VTA–PCu/PCC connectivity for intra-DMN connectivity. The
association of VTA–PCu/PCC connectivity with PCu/PCC con-
nectivity to areas beyond the classical DMN did not reach signifi-
cance in DoC patients (r = −0.35, P = 0.11; Fig. 4B, blue).
Methylphenidate Increases VTA–PCu/PCC Connectivity in a Sample of
Traumatic Brain Injury Patients Without DoC. Finally, we hypothe-
sized that if VTA–PCu/PCC connectivity is indeed a correlate of
dopaminergic neuromodulation, it should be altered by a dopa-
minergic agonist (27). We tested this hypothesis in a separate
cohort of traumatic brain injury/diffuse axonal injury patients
(n = 12) who did not have DOCs but participated in rs-fMRI
data collection in two separate sessions 2 to 4 wk apart: once with
a placebo and once with administration of 30 mg methylpheni-
date, a dopaminergic and noradrenergic agonist (see Materials
and Methods). VTA connectivity to the cluster of PCu/PCC
Fig. 2. Loss of VTA connectivity to precuneus and posterior cingulate in DoC. (A) In the control cohort used for comparisons with the DoC patients, the VTA
also showed precuneus and posterior cingulate connectivity with an additional cluster in the thalamus. (B) In a contrast of patients to these awake controls,
VTA connectivity losses were observed with PCu/PCC and mesiocortical regions, with concomitant subcortical gains (Table 1). (C) At a lowered voxel threshold,
the posterior disconnection clusters from sedation and DoC datasets spatially overlapped. (D) Display of posterior region from B on anatomical slices centered
on peak MNI coordinates. This cluster in D was used for connectivity strength extraction. Images are in neurological orientation, that is, “L” is left.
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disconnection observed in DoC patients (Fig. 2) revealed that, as
hypothesized, VTA–PCu/PCC connectivity was significantly
higher (t(11) = −1.957, P = 0.038) in the methylphenidate con-
dition (M = 0.065 ± 0.018) compared to placebo administration
(M = 0.011 ± 0.020) (SI Appendix, Fig. S3).
Discussion
When compared to healthy awake conditions, both pathological
and pharmacological states of lowered consciousness demon-
strate a substantial disruption of VTA connectivity to the PCu/
PCC, a central node of the brain’s DMN. This in vivo evidence of
a consciousness-relevant dopaminergic system dysfunction com-
mon to DoC patients and sedation is critically also associated
with a loss of specificity in the PCu/PCC’s whole-brain functional
connectivity—the stronger VTA–PCu/PCC connectivity remained,
the less the PCu/PCC’s normal connectivity pattern was perturbed.
This indicates that disrupted dopaminergic neuromodulation of
this main DMN node may at least partially underpin the com-
monly observed DMN disruptions in human perturbed states
of consciousness (2, 44). We further demonstrate that this
VTA–PCu/PCC connectivity strength can be modulated by the
dopaminergic agonist methylphenidate.
We observed a stepwise and reversible VTA–PCu/PCC dis-
connection during propofol sedation, which is in keeping with a
similar, but undiscussed, finding during dexmedetomidine [α-2
adrenergic agonist administration (45)]. However, our data link
this change in connectivity to propofol plasma levels and be-
havioral measures of cognitive access. Above all, however, we
demonstrate that this VTA disconnection from the PCu/PCC is
equally found in chronic DoC patients. This provides a neuro-
imaging demonstration of a dopamine-specific parallel between
pathological and pharmacological perturbation of consciousness.
In signaling terms, the PCu/PCC’s richness in D1 (46) and D2/
D3 dopamine receptors (47) allows its ready modulation by
dopamine, suggesting that the VTA functional disconnection
may have physiological consequences: as preclinical models of
chronic traumatic brain injury (TBI) (48) and of anesthetic
treatment (49) variously show reduced dopamine levels, lowered
VTA–PCu/PCC connectivity in rs-fMRI may coincide with or
represent lowered dopaminergic tone and therefore altered
modulation of targets. The fact that dopamine levels in rodents
only elevate back to baseline in recovery from sedation (49)
supports the assertion that the observed re-emergence of
VTA–PCu/PCC connectivity in recovery from sedation could
indeed indicate the restabilization of dopaminergic tone. This
would be consistent with sudden increases in VTA connectivity
having recently been suggested to have a mechanistic influence
in “active” emergence from propofol anesthesia in humans (50).
Despite the small sample size, the observed re-emergence of
positive VTA–PCu/PCC connectivity only in those who im-
proved and remain alive in our sample of DoC patients (in
contrast to those who did not improve and subsequently de-
ceased) suggests a possibly similar mechanism in DoC. Indeed,
the recently demonstrated deficit of presynaptic dopamine re-
lease suggests that dopaminergic agents which affect behavioral
improvements (51) may stabilize VTA functionality and con-
nectivity and/or compensate for the neuromodulatory disruption
we approximated. The authors of the related study equally hy-
pothesized the deficit revealed with [11C]-raclopride-PET to
arise from the brainstem, presumably the VTA (30). As their
analysis, however, restricted itself to dopamine in the striatum
and thalamus, they provided no data on the PCu/PCC. However,
based on the VTA’s global projections, its release deficit should
likewise affect cortical regions such as the PCu/PCC. As [11C]-
raclopride binding is dominated by a high density of dopamine
receptors in the striatum (47), we suggest that fallypride and
SCH23390 PET with concurrent rs-fMRI would provide a more
suitable tool to explore whether alterations in cortical dopamine
receptor binding in DoC patients are associated with our ob-
served connectivity deficit (52). Preclinical work by Taylor et al.
and Kenny et al. (18, 22, 53) has provided strong evidence of a
link between the arousal effects of the VTA and the D1
receptor—whereas some recent work has instead linked VTA
dopamine arousal effects to the D2 receptor (17). Further pre-
clinical studies and work in humans should therefore aim to
tease apart whether these receptors have divergent or convergent
Table 1. VTA awake connectivity and connectivity changes in propofol sedation and DoC compared to respective control conditions
Condition/ contrast
Δ connectivity







Awake volunteers — Brainstem, Cereb45 l+r, Cereb6 r, Hippocampus l+r,
pPaHC l+r, pTFusC r, TOFusC r, aPaHC l+r, Amygdala r
+00 –24 −18 1,975 0.000
Precuneus, PC −04 –64 +26 192 0.000
IC r, Amygdala r +32 +00 –20 111 0.003
Awake > moderate
(RL3)
↓Loss Precuneus, PC +14 –52 +18 424 0.000




sLOC l, OP l
+00 –56 +20 317 0.000
−36 −84 +38 213 0.009
Healthy controls — Brainstem, Thalamus l+r, pPaHC l+r, Cereb3 l+r,
Cereb45 l
−02 –22 −18 1,226 0.000
Precuneus, PC +04 –46 +18 268 0.000
Awake > DoC ↓Loss FP l, PaCig l −22 +42 +22 235 0.036
Precuneus, PC +10 –46 +24 223 0.046
DoC > awake ↑Gain LG l+r, OFusG l, Cereb1,45,6,8,9 l+r, TOFusC l+r,
Ver45,6,7,10, OFusG r, pPaHC
−34 –80 −12 5,204 0.000
Hippocampus r, TP r, Amygdala r, PP r, aSTG r, pMTG r,
IC r, aMTG r
+52 –02 −18 1,149 0.000
Hippocampus l, Brainstem −14 –18 −18 523 0.000
CONN atlas labels, peak MNI coordinates, cluster extent, and FWE-corrected P values are reported. DMN regions are in bold. Awake connectivity was
thresholded at P < 0.001 voxel level (uncorrected) and contrasts at P < 0.005 (uncorrected) with P < 0.05 cluster level (FWE corrected). ↓Loss corresponds to
decreased functional connectivity and ↑Gain to increased connectivity in comparison to control group.
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functions in this context. To this end, 18F-Fallypride PET with
concurrent rs-fMRI carried out by Nagano-Saito et al. has revealed
that dopaminergic D2/D3-mediated modulation of the PCu/PCC is
functionally important, as D2/D3 receptor binding in posterior cor-
tical regions (coincident with the PCu/PCC) is highly correlated to
DMN intranetwork connectivity strength in healthy adults (37).
Our association of VTA–PCu/PCC connectivity with the PCu/
PCC cluster’s whole-brain connectivity changes noninvasively
replicates and extends these findings by Nagano-Saito and colleagues.
In covariance with VTA–PCu/PCC connectivity strength, the
PCu/PCC connectome becomes less specialized, evidenced by
the fact that increases in connectivity occur with commonly anti-
correlated and losses to normally correlated regions (compare
SI Appendix, Fig. S4). Together, these observations suggest that
the neurobiological mechanisms by which both pharmacological
intervention and DoC pathology alter cortical brain-wide con-
nectivity may be dopamine centric. Our findings suggest that
VTA–PCu/PCC connectivity may sustain the typical architecture
of the DMN, putatively affecting how the functional connectivity
profile of normal, waking consciousness can be orchestrated on
Fig. 3. VTA–PCu/PCC connectivity strength is associated with its PCu/PCC target’s whole-brain connectivity alteration in propofol sedation. Across all conditions in
the propofol experiments, repeated measures correlations revealed that the stronger the connectivity (green arrow/axis) between the VTA (green ROI, magnified)
and its PCu/PCC target (magenta ROI, magnified), the weaker the connection (magenta arrow/axis) between this PCu/PCC target and downstream beyond-DMN
occipital gains (blue cluster) was. Downstream connectivity gains were characterized by using the PCu/PCC cluster originally identified in population-level contrasts
of VTA connectivity (Fig. 1 C and E) in new seed-to-voxel analyses (reference SI Appendix, Fig. S2B for “downstream” seed-to-voxel analyses). The dot color
represents the individual participant. The black line is overall regression line, ignoring the participant variable. All masks used for connectivity extraction were
thresholded at voxel level P < 0.005 (uncorrected) and at cluster level P < 0.05 (FWE corrected). FC = functional connectivity.
Fig. 4. VTA–PCu/PCC connectivity is associated with the strength of PCu/PCC connectivity to DMN areas in DoC patients. (A) The VTA’s connectivity strength
to its PCu/PCC target (green arrow/axis) was positively associated with the PCu/PCC’s own connectivity strength to “downstream” DMN-centric areas with
which it lost connectivity at population level (red arrow/axis). Expressly, the more VTA–PCu/PCC connectivity was preserved for each patient, the more its PCu/
PCC connectivity strength maintained a more awake-like DMN appearance. (B) The negative association of VTA–PCu/PCC connectivity strength with PCu/PCC
connectivity to a cluster of increased connectivity (such as observed for propofol sedation) did not reach significance (blue arrow/axis). Correlations of
connectivity strengths between respective seed and target masks used Spearman’s rank. Reference SI Appendix, Fig. S2A for “downstream” seed-to-voxel
analyses from which masks used for β-value extraction were extracted at voxel level P < 0.005 (uncorrected) and at cluster level P < 0.05 (FWE corrected)
thresholds. 95% CIs in gray.
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the PCu/PCC structural connectome. If this VTA-mediated func-
tional diaschisis is further substantiated with simultaneous PET and
rs-fMRI, our seed-based rs-fMRI approach could become a non-
invasive and clinically useful in vivo tool to identify consciousness-
specific dopaminergic modulatory deficits—particularly as rs-fMRI
has been suggested by both UK and US clinical bodies to be in-
corporated into the clinical management of DoC patients (40). This
approach could feasibly be extended to other transmitter systems
and disorders. Given the up-regulation of the VTA–PCu/PCC
connectivity during methylphenidate administration, the moni-
toring of this connectivity may further prove a valuable pharma-
codynamic fMRI marker for ongoing drug trials. We, however,
acknowledge that as the TBI patients who received methylpheni-
date did not have DoC, we may be observing an up-regulation of
functionally dormant but structurally intact VTA connectivity.
For clinical practice and research, this parallel between
pharmacological and pathological consciousness disruption
centered on the dopaminergic brainstem incentivizes a concep-
tual refinement to current theories of DoC. Elaborating on the
idea of coma as a brainstem structural disconnection syndrome
(54), the more heterogenous strata of DoC may be best under-
stood on a spectrum of structural and functional brainstem dis-
connections, which may have diaschisis-like consequences on
particularly important cortical network nodes. Critically, func-
tional deficits may, however, be reversible as observed in re-
covery from propofol and in the two improved DoC patients
whose VTA–PCu/PCC connectivity re-emerged—and may be
amenable to therapeutic intervention as evidenced by this con-
nectivity’s increase during methylphenidate administration.
Dormant but structurally intact brainstem neuromodulatory
connections could be a key therapeutic target for dopaminergic
and other agonists. In future work, it will be imperative to
tease apart whether the VTA is only functionally abeyant
but structurally intact in DoC patients, as this would clarify
which treatment strategies and which targets are amenable
(i.e., postsynaptic versus presynaptic mechanisms). We suggest
that despite the striking parallel between propofol sedation and
DoC centered on the VTA, this mapping of structure–function
brainstem deficits should be extended to include brainstem nu-
clei of other transmitter phenotypes, given the sporadic successes
of nondopaminergic therapies (51) in DoC. Expressly, individual
patients may have equally individual brainstem nucleic connec-
tivity (and thus transmitter system) deficits. Even in our sample
of DoC patients, brain-wide PCu/PCC connectivity alterations
also included sites of nondopaminergic brainstem nuclei of glu-
tamatergic, cholinergic, and serotonergic transmitter pheno-
types. Patients’ neuromodulatory deficits may therefore overall
be more complex and could vary relevantly between patients
both in terms of source nuclei and cortical and subcortical tar-
gets. Distinguishing how different portions of the brainstem
nuclei interact with posterior elements of the DMN as we show,
but also with components of the anterior forebrain mesocircuit,
could redefine how their “arousal signals” produce the synthesis
of the preconditions of consciousness (29). This would redefine
the previous macroscopic reports of whole brainstem discon-
nection from cortical networks (55) into a potential clinical tool
to identify which transmitter systems show deficits for a specific
patient, providing a rational basis for precision medical thera-
peutic interventions in DoC.
Despite the potential involvement of other nuclei in DoC
more broadly, the consistency of VTA disconnection across
pharmacological and pathological perturbation of consciousness
in our samples—together with the wide-ranging preexisting impli-
cations of dopamine—suggest that dopaminergic neuromodulation
from the VTA may be a particularly important component of con-
sciousness maintenance. Including in vivo biomarkers of the integrity
of VTA and dopaminergic system function such as the connectivity
demonstrated here could significantly enhance the ability of ongoing
drug trials and existent theories of DoC to account for dopa-
mine’s efficacy in improving neural and behavioral symptoms of
consciousness perturbation.
We acknowledge various limitations of our work. Firstly, our
experiments lack the temporal resolution to delineate the tem-
poral sequence of whether effects operate primarily at the VTA’s
level rather than first occurring at the cortical level. We cannot
exclude that the pharmacological and pathological effects in
propofol and DoC may originate at the level of the PCu/PCC as
previously suggested for perturbed consciousness (44)—and may
only thereafter affect the VTA. However, as this cortical region
is thought not to project to brainstem nuclei, effects at the level
of the VTA may still precede and could still strongly influence
those at the cortical level. Furthermore, as the VTA’s whole
structural connectome in humans remains unclarified, it is un-
clear whether it structurally projects to the PCu/PCC per se
(56)—although the diffuse nature of neuromodulation and the
existence of dopamine receptors in the PCu/PCC suggest so.
Additionally, the relatively short duration of scans and the lower
spatial resolution of 3T MRI imaging limits the impact of our
work (57). However, we accounted for motion, cardiac, respi-
ratory, and physiological noise artifacts in our denoising proce-
dure and have begun work to replicate these findings at 7T.
Furthermore, the dysregulation of functional connectivity cannot
yet conclusively be associated with a change in transmitter tone,
despite the supporting findings from PET (37), related preclin-
ical observations (19), and our findings with methylphenidate
suggesting so. Further work will need to use multimodal fMRI
and PET techniques with various dopamine receptor– and
transporter-specific ligands to close this knowledge gap.
In conclusion, we provide evidence of a functionally relevant
impairment in the dopaminergic system which is common to
both pharmacologically and pathologically perturbed conscious-
ness. This provides a possible translational bridge between
preclinical and clinical observations concerning dopamine’s
relevance for consciousness, as this connectivity’s disruption can
account for alterations in macroscopic connectivity. The integrity
of VTA–PCu/PCC connectivity could be a noninvasive in vivo
biomarker of the dopaminergic modulatory conditions for con-
sciousness. Its assessment could have prognostic and diagnostic
uses in intensive care settings (and possibly beyond), with a
particular potential to track pharmacological intervention ef-
fects. Altogether, these findings provide a stepping-stone toward
understanding how neurochemical influences from the brainstem
affect the rest of the brain to bring about consciousness—and
incentivize more concerted neuroimaging explorations in this
direction. Our work indicates that insights into these transmitter
systems may hold particular promise for accelerating the trans-
lation of insights and treatments from benchside to bedside.
Materials and Methods
Participants and Data Acquisition. A total of 20 healthy controls and 23 adults
who were diagnosed as in unresponsive wakefulness syndrome (UWS) (n = 9)
or MCS (n = 14) in line with current clinical guidelines were scanned using a
Magnetom 3T Tim Trio (Siemens Healthcare) at the Wolfson Brain Imaging
Centre, Addenbrooke’s Hospital, Cambridge. Structural T1-weighted acqui-
sitions were made using a fast magnetization-prepared rapid gradient-echo
(MP-RAGE) sequence (Repetition time (RT)= 2,300 ms, Echo time (TE) = 2.47
ms, 150 volumes at 1 × 1 × 1 mm2 resolution). Functional resting-state scans
used an echo-planar interleaved descending sequence consisting of 32 slices
(TR = 2,000 ms, Inversion time (TI) = 900 ms, TE = 30 ms, flip angle = 78°, 3 ×
3 × 3.75 mm2 resolution) with a scan duration of 10 min. These 23 DoC
patients (Table 2) were selected from a larger overarching dataset (n = 71).
These were all recruited from specialized long-term care centers. Patients
required a DoC diagnosis, written informed consent of participation from
their legal representative/surrogate decision maker, and capability of being
transported to Addenbrooke’s Hospital (Cambridge, United Kingdom) to be
invited to this study. Exclusion criteria included any medical condition that
made participation unsafe (decision made by clinical personnel blinded to
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study aims) or any unsuitability for the MRI scanner environment (e.g., non-
MRI safe implants), significant preexisting mental health problems, or in-
sufficient English premorbid language ability. Patients spent a total of 5 d
(including arrival and departure days) at Addenbrooke’s Hospital. After
admission, each patient underwent clinical and neuroimaging testing. Pa-
tients were not sedated at time of scan. CRS-R assessments were recorded at
least once on the day of scanning with periodic additional assessments on
the remaining days of admission. Some of these patients enrolled in a larger
ongoing observational follow-up study.
The subset of n = 23 was selected for its suitability for brainstem con-
nectivity analysis in the present study based on strict inclusion criteria: 1) a
lack of large focal brain (i.e., more than 1/3 of one hemisphere) and in
particular brainstem damage as assessed by a neuroanatomical expert
blinded to the patient’s diagnosis, (2) excessive head motion during resting-
state scanning (i.e., greater than 3 mm in translation and/or 3° in rotation),
and (3) failure of segmentation and normalization during preprocessing.
From this selection, one DoC participant was excluded after preprocessing
due to unsuccessful image coregistration. A partially overlapping subset has
previously been utilized by Luppi et al. (9).
There were no significant differences in age between the healthy control
cohort (35 ± 11.448) and DoC patients (39.4 ± 16.5) (t(37.506) = −1.022, P =
0.313). Among the subset of 22 patients, seven had follow-up rs-fMRI scans
with CRS-R assessments (SI Appendix, Table S1).
All clinical investigations were conducted in accordance with the Decla-
ration of Helsinki and all relevant ethical guidelines, and a written informed
consent of participation was obtained from patients and/or their legal rep-
resentative/surrogate decisionmaker. An ethical approval for testing patients
was provided by theNational Research Ethics Service (National Health Service,
United Kingdom; Local Research Ethics Committee reference 99/391). A brief
overview of the DoC spectrum can be found in SI Appendix.
A subset of the participants who underwent propofol treatment were
reported by Adapa and colleagues, who describe acquisition and sedation
protocols in detail (58). Briefly, in total, 26 healthy volunteers without a
history of neurological disorders (11 male) with a mean age of 34.2 y old
(range: 19 to 52 y old) were briefed on the procedures and potential side
effects of propofol sedation. Their scans were performed at the Wolfson
Brain Imaging Centre, Cambridge, United Kingdom, on a Magnetom Tim
Trio 3T (Siemens Healthcare). T1-weighted structural acquisitions were
performed using a fast MP-RAGE sequence (TR = 2,250 ms, TE = 2.99 ms, TI =
900 ms, flip angle = 9°, at 1 × 1 × 1 mm2 resolution). Functional resting-state
was acquired using an echo-planar imaging sequence in four separate ses-
sions consisting of 32 interleaved, descending slices (TR = 2,000 ms, TI = 900
ms, TE = 30 ms, flip angle = 78°, 3 × 3 × 3.75 mm2 resolution). Two partic-
ipants had to be excluded, one due to unsuccessful scan coregistration and
the other due to brainstem distortion.
In the sedation experiments, the sessions of resting-state recordings cor-
responded to dosage levels of the anesthetic agent propofol administered
via target-controlled infusion with an Alaris PK infusion pump (Carefusion).
The levels recorded were as follows: no sedation (Control, 0 μg/mL), mild
(Ramsey Level 2, 0.6 μg/mL), moderate (Ramsey Level 3, 1.2 μg/mL), and a
recovery period (58). A total of 10 min for the equilibration of plasma levels
was allowed after each administration. Then, 5-min rs-fMRI scans were
performed. The order of whether moderate or mild dosage was adminis-
tered first was randomized to control for homeostatic attuning effects.
Two trained anesthesiologists were on site for all recordings, performing
propofol administration and Ramsey Alertness/Sedation Scale assessment
before and after each scanning run. They monitored all common physio-
logical parameters using an MRI-compatible multiparameter monitor (Pre-
cesss, InVivo Corp.), surveilled participants in the scanner, and took two
blood samples (2 × 1 mL) in each condition for chromatographic analyses.
Following the resting-state scan, at each sedation level, a semantic
judgement task was collected. The experimental procedure is also detailed
by ref. 58. Briefly, the task sessions were 5.5 min in duration and made up of
alternating 30 s blocks of words and acoustically matched nonspeech buzz or
noise stimuli. Stimuli, in blocks of 8 followed by 6 s interim silences, were
presented with stimulus onset asynchrony of 3 s in silent intervals between
scans. Participants were instructed to identify with a button press whether
heard words referred to living or nonliving objects and whether nonspeech
auditory stimuli were noise or buzz type. To assess explicit memory forma-
tion during each sedation level, subjects were, upon full recovery, presented
with familiar (i.e., previously heard; targets/signal) and unfamiliar (not
previously heard; distractor/noise) items. Using the signal detection theory
model consisting of two normal distributions, one representing signal and
one representing noise, we calculated the most commonly used measure of
sensitivity, d′, as an approximation of cognitive conscious access (43). d′ is the
standardized difference between the means of signal and noise distribution,
Table 2. Demographic information for patients with DoC
Sex Age Months postinjury Etiology Diagnosis CRS-R Arousal subscore
M 21 45 TBI MCS+ 11 2
M 46 48 TBI UWS 7 2
M 57 14 TBI MCS− 12 2
M 55 15 Anoxic UWS 5 1
M 47 4 TBI MCS 10 2
M 36 34 TBI UWS 8 2
M 17 46 Anoxic UWS 11 2
F 38 13 Anoxic MCS 11 2
M 29 68 TBI MCS+ 10 2
M 23 4 TBI MCS 7 2
F 70 11 TBI MCS 9 2
F 30 6 Cerebral bleed MCS− 9 2
M 22 5 Anoxic UWS 7 2
F 62 7 Anoxic UWS 7 2
M 46 10 Anoxic UWS 5 2
M 21 7 Anoxic MCS 11 3
M 67 14 TBI MCS− 11 2
M 46 23 TBI UWS 9 2
F 55 6 Hypoxic UWS 7 2
M 28 14 TBI MCS 8 2
M 22 12 TBI MCS+ 10 2
F 28 8 Acute disseminated encephalomyelitis UWS 6 2
Diagnoses were made considering the entire clinical record instead of CRS-R alone. MCS− indicates that
patients display visual fixation and pursuit, automatic motor reactions (e.g., scratching, pulling bed sheet), or
localization to noxious stimulation. MCS+ classification indicates that patients consistently and repeatedly fol-
lowed simple commands or intelligibly verbalized (69, 70). Patients classified as MCS showed such behavior but
only intermittently. CRS-R is the highest score recorded by the attending physician for the day of the scanning
session. CRS-R scores were collected at least once on the day of scanning with periodic additional assessments on
remaining visit days.
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that is, the higher d′ is, the more readily a signal is detected, as the subject is
better able to distinguish old and new items.
Ethical approval for the sedation experiments was obtained from the
Cambridgeshire 2 Regional Ethics Committee. Written informed consent for
all research was obtained from all participants prior to any experiments.
The TBI patients without disorders of consciousness who received meth-
ylphenidate were a subset (n = 12, mean age 34.4 ± 12.8) of patients from
the larger dataset (n = 15), which Manktelow et al. (59) describe in detail.
The subselection of n = 12 (see Table 3) was based on the same strict in-
clusion criteria set out for the DoC cohort, with scans from three patients not
meeting these. These data were acquired using the same sequences as the
DoC patients and their control cohort on two different research visits sep-
arated by 2 to 4 wk. TBI patients received 30 mg MPh (30 mg dose visually
indistinguishable from lactose placebo) either on their first or second visit,
randomized using a Latin square design. Dosages were based on comparable
doses used in previous studies in healthy participants as well as National
Institute for Health and Care Excellence guidelines for medication in adults
(https://www.nice.org.uk). These patients received no other catecholamin-
ergic/dopaminergic agents in the period between research visits. On the
visit, 75 min were allowed after MPh administration to ensure that the peak
plasma levels of MPh were reached. After these 75 min, the volunteers
completed an MRI scan, which included task and resting-state fMRI as well as
structural image acquisitions [see Manktelow et al. (59)]. Written informed
consent was obtained from all participants and/or legal surrogate decision
makers prior to any experiments or brain scans.
Spatial and Temporal Preprocessing. Preprocessing for all scans was performed
using the CONN functional connectivity toolbox [19c (60)], running in
MATLAB (2018b, MathWorks, Inc.).
For spatial preprocessing, functional images were first slice-time corrected,
centered to (0,0,0) Montreal Neurological Institute (MNI) coordinates, real-
igned to correct for movement, and were subjected to Artifact detection
tools (ART)-based identification of outlier scans for scrubbing. Following
this, the structural image was coregistered to the mean functional image
and then segmented and spatially normalized to the MNI-152 template.
Functional images were then normalized to the MNI-152 template based on
parameters obtained from structural normalization and smoothed with a
6-mm Gaussian kernel at full-width half maximum.
Temporal preprocessing employed masks for white matter (WM) and
cerebrospinal fluid (CSF) produced with structural segmentation to regress
out physiological noise in the blood oxygenation level dependent (BOLD)
signal as it can otherwise influence functional connectivity estimates. This
method called CompCor (61) regresses out the first five principal components
of WM and CSF signals, movement parameters obtained from realignment,
and their first-order derivatives—alleviating the need for global signal re-
gression, which can equally perturb functional connectivity (FC) estimates
(62). Additionally, anatomical CompCor scrubs outlier scans that the ART
toolbox method has characterized. Thereafter, our data were linearly
detrended and filtered using a high-pass filter of 0.008 Hz.
VTA Primary Functional Connectivity Analyses. The VTA ROI we used is from
the HAAN (39). We chose it based on being a histologically characterized and
thus dopamine-specific ROI. Its faithful coregistration to our anatomical and
functional scans was extensively assessed visually.
Functional connectivity—the temporal correlation of regional timeseries—is
conceptualized to represent information sharing and dynamic cooperation
(63), identifying spatially segregated functional units at global scales. Here, FC
was calculated using CONN in the form of seed-to-voxel analyses for assessing
effects in the whole brain. Temporal correlations for the dopaminergic VTA
seed (and in secondary analyses for its “downstream” targets) were computed
for all other voxels in the brain using a general linear model (GLM). The
functional connectivity analyses produced seed-to-voxel parameter estimate
images, which were entered into population-level analyses; we used inde-
pendent sample Student’s t tests to compute differences from healthy
controls for DoC patients and paired-sample Student’s t tests for differences
from the awake state for the propofol dataset. We report results thresh-
olded at voxel level P < 0.005 (uncorrected) and cluster level P < 0.05 (family-wise
error [FWE] corrected for multiple comparisons) for a valid voxel-wise inference
approach (64).
Correlations of VTA Connectivity with “Downstream” Whole-Brain Connectivity
of Targets and Behavior. The clusters of altered VTA connectivity that were
revealed in primary functional connectivity analyses were entered as seeds
into subsequent seed-to-voxel analyses in their respective cohorts to com-
pute differences from awake controls. This was to reveal altered “down-
stream” connectivities of VTA targets. All connectivity clusters were
extracted as binary masks. To test our hypothesis that VTA connectivity may
have neuromodulatory effects on its targets (and resultant network archi-
tectures), we extracted eigenvalues of connectivity strength (β-estimates
from GLM) per participant per condition for both VTA ⇌ primary-target
connectivity and target ⇌ downstream cluster connectivity. To approxi-
mate whether there is a neuromodulatory relationship between VTA ⇌
target connectivity alterations and target ⇌ downstream connectivity, we
assessed how these two functional connectivity strengths covaried for pa-
tients and sedated volunteers, respectively.
All correlations were performed using RStudio with ggplot2 for DoC
patients and for propofol experiments with the rmcorr toolbox (65) using
analysis of covariance to account for nonindependence among the repeated
observations (awake, mild and moderate sedation, and recovery) by statis-
tically adjusting for interindividual variability. For further statistical strin-
gency, the “rmcorr” correlations were bootstrapped (n = 1,000) to conform
to 95% CIs, and correlations for DoC patients used Spearman’s rank. As
behavioral measures, we included the sensitivity index d′ for the propofol
sedation dataset and, for patients with DoC, the clinical bedside assessments
of highest CRS-R [score and highest CRS-R arousal subscore at time of scan
(66, 67)]. Based on CRS-R improvement and clinical assessment, we identified
which DoC patients who had follow-up rs-fMRI scans had respectively im-
proved of deteriorated and calculated their VTA–PCu/PCC change (SI Ap-
pendix, Table SM).
Data Availability. The fully processed data and images underpinning the
analyses and figures in the present manuscript have been deposited to the
repository available at https://doi.org/10.17863/CAM.72170 (68). Due to pa-
tient privacy concerns, raw neuroimaging and behavioral data are available
upon request by qualified researchers. The UK Health Research Authority
mandates that the confidentiality of data is the responsibility of Chief In-
vestigators for the initial studies (in this case, J.A. and D.K.M. and anyone to
whom this responsibility is handed—for example, in the context of retirement
Table 3. Demographic information for TBI patients who received methylphenidate
Sex Age Months postinjury Etiology Lesion description GCS
M 27 25 TBI Hemorrhagic contusions in bilateral frontal lobes 7
M 53 32 TBI Right subarachnoid hemorrhage and subdural hematoma 14
M 49 27 TBI Hemorrhagic contusion left lentiform nucleus 8
F 55 17 TBI Subarachnoid hemorrhage in left frontoparietal cortex 12
M 29 14 TBI Hemorrhagic contusions in left temporal lobe/basal ganglia/thalamus 5
M 19 32 TBI Subarachnoid hemorrhage in left interpeduncular fossa 7
M 21 39 TBI Multiple petechial hemorrhages, obliterated basal cisterns 3
M 36 11 TBI Epidural hematoma right temporal lobe 6
M 26 25 TBI Intraventricular hemorrhage 7
F 34 41 TBI Intracerebral hemorrhage and right temporal/parietal contusions NA
M 43 7 TBI Right subarachnoid hemorrhage and subdural hematoma 10
F 21 9 TBI Unavailable NA
The lesion diagnostic description was made by a neurologist and/or neuroradiologist. When NA or unavailable, the injury occurred abroad with detailed
records unavailable. GCS = Glasgow coma scale score at time of admission.
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or transfer to another institution). Requests will be considered on a case-
by-case basis, assessing the feasibility and appropriateness of the proposed
study, and the capacity to maintain the required levels of data security
consistent with the original approved research ethics approval and the pa-
tient information sheet that was the basis of consent obtained. The CONN
toolbox is freely available online (https://www.nitrc.org/projects/conn). The
HAAN atlas, containing the VTA, is freely available from the Athinoula A.
Martinos Center for Biomedical Imaging (https://www.nmr.mgh.harvard.
edu). The rmcorr and ggplot2 toolboxes are available via CRAN in RStudio
(https://www.R-project.org/).
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